Fed. Circ. Won't Block Amgen's Herceptin Biosimilar

March 6, 2020

The Federal Circuit shot down Genentech's latest attempt to block Amgen from selling a biosimilar version of its blockbuster cancer drug Herceptin. Read more here

Jump to Page

By using this site, you agree to our updated Privacy Policy and our Terms of Use.